NPEPPS Is a Druggable Driver of Platinum Resistance
©2024 The Authors; Published by the American Association for Cancer Research..
There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which is used in primary and metastatic settings in many cancer types. In bladder cancer, platinum-based chemotherapy leads to better outcomes in a subset of patients when used in the neoadjuvant setting or in combination with immunotherapy for advanced disease. Despite such promising results, extending the benefits of platinum drugs to a greater number of patients is highly desirable. Using the multiomic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified puromycin-sensitive aminopeptidase (NPEPPS) as a driver of cisplatin resistance. NPEPPS depletion sensitized resistant bladder cancer cells to cisplatin in vitro and in vivo. Conversely, overexpression of NPEPPS in sensitive cells increased cisplatin resistance. NPEPPS affected treatment response by regulating intracellular cisplatin concentrations. Patient-derived organoids (PDO) generated from bladder cancer samples before and after cisplatin-based treatment, and from patients who did not receive cisplatin, were evaluated for sensitivity to cisplatin, which was concordant with clinical response. In the PDOs, depletion or pharmacologic inhibition of NPEPPS increased cisplatin sensitivity, whereas NPEPPS overexpression conferred resistance. Our data present NPEPPS as a druggable driver of cisplatin resistance by regulating intracellular cisplatin concentrations.
SIGNIFICANCE: Targeting NPEPPS, which induces cisplatin resistance by controlling intracellular drug concentrations, is a potential strategy to improve patient responses to platinum-based therapies and lower treatment-associated toxicities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cancer research - (2024) vom: 27. März, Seite OF1-OF20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jones, Robert T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1158/0008-5472.CAN-23-1976 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370255526 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370255526 | ||
| 003 | DE-627 | ||
| 005 | 20240404235204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-23-1976 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM370255526 | ||
| 035 | |a (NLM)38535994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jones, Robert T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NPEPPS Is a Druggable Driver of Platinum Resistance |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a ©2024 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which is used in primary and metastatic settings in many cancer types. In bladder cancer, platinum-based chemotherapy leads to better outcomes in a subset of patients when used in the neoadjuvant setting or in combination with immunotherapy for advanced disease. Despite such promising results, extending the benefits of platinum drugs to a greater number of patients is highly desirable. Using the multiomic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified puromycin-sensitive aminopeptidase (NPEPPS) as a driver of cisplatin resistance. NPEPPS depletion sensitized resistant bladder cancer cells to cisplatin in vitro and in vivo. Conversely, overexpression of NPEPPS in sensitive cells increased cisplatin resistance. NPEPPS affected treatment response by regulating intracellular cisplatin concentrations. Patient-derived organoids (PDO) generated from bladder cancer samples before and after cisplatin-based treatment, and from patients who did not receive cisplatin, were evaluated for sensitivity to cisplatin, which was concordant with clinical response. In the PDOs, depletion or pharmacologic inhibition of NPEPPS increased cisplatin sensitivity, whereas NPEPPS overexpression conferred resistance. Our data present NPEPPS as a druggable driver of cisplatin resistance by regulating intracellular cisplatin concentrations | ||
| 520 | |a SIGNIFICANCE: Targeting NPEPPS, which induces cisplatin resistance by controlling intracellular drug concentrations, is a potential strategy to improve patient responses to platinum-based therapies and lower treatment-associated toxicities | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Scholtes, Mathijs |e verfasserin |4 aut | |
| 700 | 1 | |a Goodspeed, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Akbarzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mohapatra, Saswat |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Lily Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Vekony, Hedvig |e verfasserin |4 aut | |
| 700 | 1 | |a Jean, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Tilton, Charlene B |e verfasserin |4 aut | |
| 700 | 1 | |a Orman, Michael V |e verfasserin |4 aut | |
| 700 | 1 | |a Romal, Shahla |e verfasserin |4 aut | |
| 700 | 1 | |a Deiter, Cailin |e verfasserin |4 aut | |
| 700 | 1 | |a Kan, Tsung Wai |e verfasserin |4 aut | |
| 700 | 1 | |a Xander, Nathaniel |e verfasserin |4 aut | |
| 700 | 1 | |a Araki, Stephanie P |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Molishree |e verfasserin |4 aut | |
| 700 | 1 | |a Javaid, Mahmood |e verfasserin |4 aut | |
| 700 | 1 | |a Clambey, Eric T |e verfasserin |4 aut | |
| 700 | 1 | |a Layer, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Laajala, Teemu D |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudi, Tokameh |e verfasserin |4 aut | |
| 700 | 1 | |a Zuiverloon, Tahlita C M |e verfasserin |4 aut | |
| 700 | 1 | |a Theodorescu, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Costello, James C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g (2024) vom: 27. März, Seite OF1-OF20 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:03 |g pages:OF1-OF20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-23-1976 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 03 |h OF1-OF20 | ||